The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Enhanced glucose control for preventing and treating diabetic neuropathy
Open accessAbstract
BACKGROUND: There are two types of diabetes. Type 1 diabetes affects younger people and needs treatment with insulin injections. Type 2 diabetes affects older people and can usually be treated by diet and oral drugs. Diabetic neuropathy affects 10% of patients with diabetes mellitus at diagnosis and 40% to 50% after 10 years. Enhanced glucose control is the best studied intervention for the prevention of this disabling condition but there have been no systematic reviews of the evidence. OBJECTIVES: To examine the evidence for enhanced glucose control in the prevention of distal symmetric polyneuropathy in people with type 1 and type 2 diabetes. SEARCH METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register (30 January 2012), CENTRAL (2012, Issue 1), MEDLINE (1966 to January 2012) and EMBASE (1980 to January 2012) for randomized controlled trials of enhanced glucose control in diabetes mellitus. SELECTION CRITERIA: We included all randomized, controlled studies investigating enhanced glycemic control that reported neuropathy outcomes after at least one year of intervention. Our primary outcome measure was annual development of clinical neuropathy defined by a clinical scale. Secondary outcomes included motor nerve conduction velocity and quantitative vibration testing. DATA COLLECTION AND ANALYSIS: Two authors independently reviewed all titles and abstracts identified by the database searches for inclusion. Two authors abstracted data from all included studies with a standardized form. A third author mediated conflicts. We analyzed the presence of clinical neuropathy with annualized risk differences (RDs), and conduction velocity and quantitative velocity measurements with mean differences per year. MAIN RESULTS: This review identified 17 randomized studies that addressed whether enhanced glucose control prevents the development of neuropathy. Seven of these studies were conducted in people with type 1 diabetes, eight in type 2 diabetes, and two in both types. A meta-analysis of the two studies that reported the primary outcome (incidence of clinical neuropathy) with a total of 1228 participants with type 1 diabetes revealed a significantly reduced risk of developing clinical neuropathy in those with enhanced glucose control, an annualized RD of -1.84% (95% confidence interval (CI) -1.11 to -2.56). In a similar analysis of four studies that reported the primary outcome, involving 6669 participants with type 2 diabetes, the annualized RD of developing clinical neuropathy was -0.58% (95% CI 0.01 to -1.17). Most secondary outcomes were significantly in favor of intensive treatment in both populations. However, both types of diabetic participants also had a significant increase in severe adverse events including hypoglycemic events. AUTHORS' CONCLUSIONS: According to high-quality evidence, enhanced glucose control significantly prevents the development of clinical neuropathy and reduces nerve conduction and vibration threshold abnormalities in type 1 diabetes mellitus. In type 2 diabetes mellitus, enhanced glucose control reduces the incidence of clinical neuropathy, although this was not formally statistically significant (P = 0.06). However, enhanced glucose control does significantly reduce nerve conduction and vibration threshold abnormalities. Importantly, enhanced glucose control significantly increases the risk of severe hypoglycemic episodes, which needs to be taken into account when evaluating its risk/benefit ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
(2008) · Cited by 3,790
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202
Abbott, C. A., Carrington, A. L., Ashe, H., Bath, S., Every, L. C., Griffiths, J., Hann, A. W., Hussein, A., Jackson, N., Johnson, K. E., et al. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00698.x · Cited by 1,056
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Shichiri, M., Kishikawa, H., Ohkubo, Y., & Wake, N. (2000) · PubMed · Cited by 727
Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus
Partanen, J., Niskanen, L., Lehtinen, J., Mervaala, E., Siitonen, O., & Uusitupa, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330203 · Cited by 656
Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy
Boulton, A. J. M., Gries, F. A., & Jervell, J. A. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199806)15:6<508::aid-dia613>3.0.co;2-l · Cited by 378
Glycemic control and complications in type 2 diabetes mellitus
Stolar, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.004 · Cited by 356
Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Ganes, T., Kierulf, P., Smeland, E., Sandvik, L., & Aagenaes, O. (1986) · BMJ · doi:10.1136/bmj.293.6556.1195 · Cited by 329
DCCT Research Group, B. N. (1995) · Annals of Neurology · doi:10.1002/ana.410380607 · Cited by 283
Lauritzen, T., Frost-Larsen, K., Larsen, H.-W., Deckert, T., & The Steno Study Group (1985) · Diabetes · doi:10.2337/diab.34.3.s74 · Cited by 252
Holman, R. R., Mayon-White, V., Orde-Peckar, C., Steemson, J., Smith, B., Mcpherson, K., Rizza, C., Knight, A. H., Dornan, T. L., Howard-Williams, J., et al. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92586-2 · Cited by 184
The Discovery of Type 1 Diabetes
Gale, E. A. M. (2001) · Diabetes · doi:10.2337/diabetes.50.2.217 · Cited by 157
Azad, N., Emanuele, N., Abraira, C., Henderson, W. G., Colwell, J. A., Levin, S. R., Nuttall, F. Q., Comstock, J. P., Sawin, C. T., Silbert, C. K., et al. (1999) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(99)00062-8 · Cited by 130
Amthor, K.-F., Dahl‐Jørgensen, K., Tj, B., Heier, M., Sandvik, L., Aagen�s, �., & Hanssen, K. F. (1994) · Diabetologia · doi:10.1007/bf00403376 · Cited by 110
Quantitating Overall Neuropathic Symptoms, Impairments, and Outcomes
Dyck, P. J. B., Hughes, R. A., & O’Brien, P. C. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-9491-7.50043-0 · Cited by 85
Self-citationLinn, T., Ortac, K., Laube, H., & Federlin, K. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90180-8 · Cited by 79
Jakobsen, J., Christiansen, J. S., Kristoffersen, I. B., Christensen, C., Hermansen, K., Schmitz, A., & Mogensen, C. E. (1988) · Diabetes · doi:10.2337/diab.37.4.452 · Cited by 68
Therapeutic Strategies for Diabetic Neuropathy
Habib, A. A., & Brannagan, T. H. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0093-7 · Cited by 46
Effect of Blood Glucose Control on Peripheral Nerve Function in Diabetic Patients
Service, F. J., Daube, J. R., Zimmerman, B. R., O’Brien, P. C., Swanson, C., Brennan, M., & Dyck, P. J. B. (1983) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)18769-7 · Cited by 40
Severity and Staging of Diabetic Polyneuropathy
(2003) · Thieme eBooks · doi:10.1055/b-0034-83069 · Cited by 37
Glycemic control in the prevention of diabetic complications
Ratner, R. E. (2001) · Clinical cornerstone · doi:10.1016/s1098-3597(01)90027-4 · Cited by 27
Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin treatment
Tovi, J., Svanborg, E., Nilsson, B.-Y., & Engfeldt, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb01746.x · Cited by 25
Diabetic Neuropathy: Effects of Intensified Glycaemic Control with Multiple Insulin Injections
Hotta, N., Kawamori, R., Sano, T., Kakuta, H., Kamada, T., & Sakamoto, N. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00211.x · Cited by 3
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Self-citationEpidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes
Hicks, C. W., & Selvin, E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1212-8 · Cited by 798
The Role of Oxidative Stress and Antioxidants in Diabetic Wound Healing
Deng, L., Du, C., Song, P., Chen, T., Rui, S., Armstrong, D. G., & Deng, W. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8852759 · Cited by 763
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Metadata
- Authors
- Callaghan, B. C., Little, A. A., Feldman, E. L., & Hughes, R. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-06-13
- Volume
- 2012
- Issue
- 6
- Pages
- CD007543-CD007543
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2113880168
- Cited by
- 584
- References
- 32
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.